Flubendazole enhances the activity of Vinca alkaloids in vivo. Sublethally irradiated SCID mice were injected subcutaneously with OCI-AML2 cells (n = 40; 10 per group). After implantation, mice were treated with (A) 15 mg/kg flubendazole, 0.3 mg/kg vinblastine, a combination of flubendazole and vinblastine, or vehicle control; or (B) 20 mg/kg flubendazole, 0.25 mg/kg vincristine, a combination of flubendazole and vincristine, or vehicle control. After 16 (A) or 18 (B) days, mice were killed and tumors were excised, measured, and weighted. (C) Sublethally irradiated SCID mice were injected subcutaneously with OCI-AML2 cells (n = 40; 10 per group). Eleven days after injection, when tumors were established (eg, tumor volume = 32 mm3), mice were treated with 50 mg/kg flubendazole, 0.25 mg/kg vincristine (VCR), the combination of flubendazole and VCR, or vehicle control. Tumor volume was measured over time with calipers. Data are the mean ± SD tumor weight. A representative experiment is shown. #P < .05, *P < .01, **P < .001, compared with controls (unpaired t test).
